COMMITMENTS & CONTINGENCIES (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended
COMMITMENTS & CONTINGENCIES (Detail Textuals) - USD ($)	Mar. 23, 2017	Mar. 31, 2017	Feb. 15, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Down payment under joint venture agreement		$ 250,000
Deferred rent payable		$ 7,945		$ 8,513
Binding letter of intent \| Alamo CBD, LLC ("Alamo CBD")
Commitments And Contingencies [Line Items]
Maximum capital required to pay off existing debt			$ 1,000,000
Contractual Joint Venture Agreement \| Vyripharm Enterprises, LLC ("Vyripharm") and Alamo CBD
Commitments And Contingencies [Line Items]
Total contribution in joint venture	$ 5,000,000
Per year contribution in joint venture	1,000,000
Payment made in first anniversary of joint venture	1,000,000
Payment made in second anniversary of joint venture	1,000,000
Payment made in third anniversary of joint venture	1,000,000
Payment made in fourth anniversary of joint venture	1,000,000
Payment made in fifth anniversary of joint venture	$ 1,000,000
Description of conditions for fail in payments	If IHI should fail to timely pay the initial $1,000,000 as set forth above, this Agreement shall terminate and neither Party shall have further obligation to the other. If IHI should fail to pay the second $1,000,000 payment within thirty (30) days following the second anniversary of the Effective Date, then this Agreement shall terminate and Alamo CBD shall forfeit four-fifths (4/5) of its revenue share from any product that has been developed or is subsequently developed by Vyripharm which uses cannabis oil or processes supplied to Vyripharm by IHI. If IHI should fail to pay the third $1,000,000 payment within thirty (30) days following the third anniversary of the Effective Date, then this Agreement shall terminate and IHI shall forfeit three-fifths (3/5) of its revenue share from any product that has been developed or is subsequently developed by Vyripharm which uses medical cannabis oil or processes supplied to Vyripharm by IHI. If IHI should fail to pay the fourth $1,000,000 payment within thirty (30) days following the fourth anniversary of the Effective Date, then this Agreement shall terminate and IHI shall forfeit four-fifths (2/5) of its revenue share from any product that has been developed or is subsequently developed by Vyripharm which uses medical cannabis oil or processes supplied to Vyripharm by IHI. If IHI should fail to pay the fifth $1,000,000 payment within thirty (30) days following the fifth anniversary of the Effective Date, then this Agreement shall terminate and IHI shall forfeit one-fifth (1/5) of its revenue share from any product that has been developed or is subsequently developed by Vyripharm which uses medical cannabis oil or processes supplied to Vyripharm by IHI. With the exception of cost sharing for the filing of, prosecuting and maintaining any joint patent applications pursuant to Paragraph 6 of this Agreement, and unless the Parties mutually agree, IHI shall have no further financial obligations under this Agreement during the Initial Term. The Parties shall otherwise bear their own costs in carrying out their respective responsibilities under this Agreement.
Description of conditions for pay out structure	Due to the Fees and schedule that Vyripharm must attained with the institutions in the TMC the only pay out structure that we can approve is the following: The first $1,000,000 shall be paid as follow: Option 1) Upfront all the $1,000,000.00 for the year if excess funds are raised (Over the $10,250,000), Option 2) 5% of funds up to $10,250,000, which are raised from presentations to investors in which Vyripharm participates; Option 3) if less than $10,250,000 is raised in 2017, then IHI will/should make a $250,000 down payment to Vyripharm, and pay another $250,000 at the end of the 2nd quarter of 2017. If IHI does not have the funds to pay another $250,000 in the 3rd quarter of 2017, then that payment can be pushed back to the 4th quarter with the final payment of $500,000 owed to Vyripharm in or at the end of the 4th quarter of 2017
Down payment under joint venture agreement	$ 250,000
Initial term of the Joint Venture	5 years